- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
CDKN1A Antibody (C-term)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP13468b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AP13468b-ev20 | 20 ug 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
CDKN1A Antibody (C-term) - Product info | |
| Application | WB, IHC
|
| Primary Accession | P38936 |
| Other Accession | NP_000380.1, NP_510867.1 |
| Reactivity | Human, Mouse |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 18119 Da |
CDKN1A Antibody (C-term) - Additional info | |
| Gene ID 1026 | |
| Other Names CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1; Cyclin-dependent kinase inhibitor 1; CDK-interacting protein 1; Melanoma differentiation-associated protein 6; p21 | |
| Target/Specificity This CDKN1A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 116-146 amino acids from the C-terminal region of human CDKN1A. | |
| Dilution WB~~1:100~500WB~~1:1000 IHC~~1:10~50 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions CDKN1A Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
CDKN1A Antibody (C-term) - Protein Information | |
| Name CDKN1A | |
| Synonyms CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WA | |
| Function May be the important intermediate by which p53/TP53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin- dependent kinase substrates and blocking cell cycle progression Functions in the nuclear localization and assembly of cyclin D- CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex | |
| Cellular Location Cytoplasm. Nucleus. | |
| Tissue Location Expressed in all adult tissues, with 5-fold lower levels observed in the brain | |
CDKN1A Antibody (C-term) - Related products
AP13468b: CDKN1A Antibody (C-term)
AP3187a: Phospho-p21Cip1-pS130 Antibody
AP3188a: Phospho- P21CIP1-S146 Antibody
AP3189a: Phospho-P21CIP1-T145 Antibody
AP3190a: Phospho-P21CIP1-T57 Antibody
AP7527b: p21 (CDKN1A) Antibody (C-term)
AP9311a: P21Cip1-S130 Antibody
RI10982: CDKN1A predesign siRNA
DC00876: Human CDKN1A cDNA Clone
LY10135a: CDKN1A Over-expression Lysate
BP3187a: Phospho-p21Cip1-pS130 Antibody Blocking Peptide
BP3188a: Phospho- P21CIP1-S146 Antibody Blocking Peptide
BP3189a: Phospho-P21CIP1-T145 Antibody Blocking Peptide
BP3190a: Phospho-P21CIP1-T57 Antibody Blocking Peptide
BP7527b: CDKN1A Antibody (C-term) Blocking Peptide
CDKN1A Antibody (C-term) - Application data
-
CDKN1A Antibody (C-term) (Cat. #AP13468b) western blot analysis in Jurkat cell line lysates (35ug/lane).This demonstrates the CDKN1A antibody detected the CDKN1A protein (arrow).
-
CDKN1A Antibody (C-term) (Cat. #AP13468b) western blot analysis in mouse Neuro-2a cell line lysates (35ug/lane).This demonstrates the CDKN1A antibody detected the CDKN1A protein (arrow).
-
CDKN1A Antibody (C-term) (Cat. #AP13468b)immunohistochemistry analysis in formalin fixed and paraffin embedded human breast carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining.This data demonstrates the use of CDKN1A Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.
CDKN1A Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.
REFERENCES
Hu, F., et al. Oncogene 29(40):5464-5474(2010) Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Jiang, P., et al. Acta Biochim. Biophys. Sin. (Shanghai) 42(9):671-676(2010) Ho-Pun-Cheung, A., et al. Pharmacogenomics J. (2010) In press : Do Nascimento Borges, B., et al. In Vivo 24(4):579-582(2010)
